Further advancing this finding, we devised a DMA‐based therapeutic approach that hindered the communication between CAFs and breast cancer cells to reduce TGF‐β signalling levels in breast cancer cells at the primary tumour and impair multiorgan metastasis. Here, TGFB1 is linked to breast cancer.